

Serial No.: 10/023,14

Art Unit: 1617

- 3 -

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 to 5 (Cancelled).

6 (Previously presented) A tablet formulation according to Claim 16 wherein the core and the casing layer both comprise a compacted mixture of components.

7 (Previously presented). A tablet formulation according to Claim 16 wherein the release retarding coating is an enteric polymer.

8 (Previously presented). A tablet formulation according to Claim 16 further comprising one or more sub-coats beneath the release retarding coating layer.

9 (Previously presented). A tablet formulation according to Claim 16 further comprising one or more over-coats above the release retarding coating layer.

10 to 15 (Cancelled).

16 (Currently amended). A tablet formulation for oral administration comprising amoxycillin and clavulanate in a ratio of 30:1 to 1:1 in which a portion of the amoxycillin and all of the clavulanate is in a central core which is surrounded by a release-retarding coating layer and the remainder of the amoxycillin is in a casing layer surrounding the core, such that there is an initial quick release of amoxycillin and clavulanate from the casing layer and a sustained release of amoxycillin and clavulanate from the core.

17 (Previously presented). A tablet formulation according to Claim 16 for oral administration twice a day.

18 (Previously presented). A method of treating a bacterial infection in a patient in need thereof, which method comprises administering to said patient an effective amount of a formulation according to Claim 16.